Century Therapeutics(IPSC.US)

Last Updated 19:00:00 ET
longbridge loading

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Unusual Whales·
US
IPSC
+0.45%
Unusual Whales·
US
IPSC
+0.45%

Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session

benzinga_article·
US
ICCM
-10.82%
US
IPSC
+0.45%
US
.IXIC
+0.31%
benzinga_article·
US
ICCM
-10.82%
US
IPSC
+0.45%
US
.IXIC
+0.31%

Century Therapeutics shares are trading higher after Mizuho initiated coverage on the stock with an Outperform rating and announced an $8 price target.

benzinga_article·
US
IPSC
+0.45%
US
FBT
-0.71%
US
SBIO
+1.29%
benzinga_article·
US
IPSC
+0.45%
US
FBT
-0.71%
US
SBIO
+1.29%

Cor appoints Brent Pfeiffenberger to board as independent director

TradingView·
US
IPSC
+0.45%
US
BMY
+0.40%
TradingView·
US
IPSC
+0.45%
US
BMY
+0.40%

Century Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
IPSC
+0.45%
Earnings Watch·
US
IPSC
+0.45%

Century Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
IPSC
+0.45%
Earnings Watch·
US
IPSC
+0.45%

12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga_article·
US
BBH
-0.17%
US
SBIO
+1.29%
US
COCP
-1.50%
benzinga_article·
US
BBH
-0.17%
US
SBIO
+1.29%
US
COCP
-1.50%
© 2026 Longbridge｜Disclaimer